{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:30Z","timestamp":1793405310768,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEUONC"],"DOI":"10.1093\/neuonc\/now158","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T23:09:22Z","timestamp":1470870562000},"page":"now158","source":"Crossref","is-referenced-by-count":21,"title":["Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas"],"prefix":"10.1093","author":[{"given":"Regina I.","family":"Jakacki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Kieran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J.","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Fangusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,10]]},"reference":[{"key":"2016081020091514000_now158v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70075-3"},{"key":"2016081020091514000_now158v1.2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W"},{"key":"2016081020091514000_now158v1.3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/111.6.1355"},{"key":"2016081020091514000_now158v1.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1755"},{"key":"2016081020091514000_now158v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.08.051"},{"key":"2016081020091514000_now158v1.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bd1326"},{"key":"2016081020091514000_now158v1.7","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000042321.94839.78"},{"key":"2016081020091514000_now158v1.8","doi-asserted-by":"crossref","unstructured":"Widemann BC Babovic-Vuksanovic D Dombi E . phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014.","DOI":"10.1002\/pbc.25041"},{"key":"2016081020091514000_now158v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou004"},{"key":"2016081020091514000_now158v1.10","doi-asserted-by":"publisher","DOI":"10.1080\/08977190400000833"},{"key":"2016081020091514000_now158v1.11","doi-asserted-by":"publisher","DOI":"10.2174\/156800909789056980"},{"key":"2016081020091514000_now158v1.12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313830200"},{"key":"2016081020091514000_now158v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.420"},{"key":"2016081020091514000_now158v1.14","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31824b3a76"},{"key":"2016081020091514000_now158v1.15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.437"},{"key":"2016081020091514000_now158v1.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.10.1461"},{"key":"2016081020091514000_now158v1.17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318207b031"},{"key":"2016081020091514000_now158v1.18","doi-asserted-by":"crossref","unstructured":"National Institutes of Health, Consensus Development Conference. Neurofibromatosis: Conference Statement. 1988;45:575\u2013578.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"2016081020091514000_now158v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.compmedimag.2004.03.002"},{"key":"2016081020091514000_now158v1.20","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000435744.57038.af"},{"key":"2016081020091514000_now158v1.21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-1224"},{"key":"2016081020091514000_now158v1.22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24873"},{"key":"2016081020091514000_now158v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou235"},{"key":"2016081020091514000_now158v1.24","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000250332.89420.e6"},{"key":"2016081020091514000_now158v1.25","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0106"},{"key":"2016081020091514000_now158v1.26","doi-asserted-by":"publisher","DOI":"10.1017\/S0012162206002131"},{"key":"2016081020091514000_now158v1.27","doi-asserted-by":"crossref","unstructured":"Widemann BC Marcus LJ Fisher MJ . phase I study of the MEK1\/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). Astract Number 10018. Paper presented at: ASCO MEETING ABSTRACTS 2014;Chicago.","DOI":"10.1200\/jco.2014.32.15_suppl.10018"},{"key":"2016081020091514000_now158v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70414-X"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/19\/2\/289\/17682046\/now158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T07:53:58Z","timestamp":1568274838000},"score":1,"resource":{"primary":{"URL":"http:\/\/neuro-oncology.oxfordjournals.org\/lookup\/doi\/10.1093\/neuonc\/now158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,10]]},"references-count":28,"alternative-id":["10.1093\/neuonc\/now158"],"URL":"https:\/\/doi.org\/10.1093\/neuonc\/now158","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,10]]}}}